Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 1
2012 2
2013 1
2014 1
2015 2
2016 1
2018 1
2019 2
2020 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Hosomi Y, et al. J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4. J Clin Oncol. 2020. PMID: 31682542 Clinical Trial.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R, Kobayashi K, Usuki J, Yomota M, Nishitsuji M, Shimokawa T, Ando M, Hino M, Hagiwara K, Miyanaga A, Seike M, Kubota K, Gemma A; North East Japan Study group. Noro R, et al. Thorac Cancer. 2020 Jul;11(7):1876-1884. doi: 10.1111/1759-7714.13472. Epub 2020 May 18. Thorac Cancer. 2020. PMID: 32421226 Free PMC article. Clinical Trial.
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.
Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group. Morikawa N, et al. Expert Opin Pharmacother. 2015 Mar;16(4):465-72. doi: 10.1517/14656566.2015.1002396. Epub 2015 Jan 19. Expert Opin Pharmacother. 2015. PMID: 25597331
A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K; North East Japan Study Group. Usui K, et al. Lung Cancer. 2016 Sep;99:131-6. doi: 10.1016/j.lungcan.2016.07.003. Epub 2016 Jul 5. Lung Cancer. 2016. PMID: 27565928 Clinical Trial.
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024.
Oizumi S, Takamura K, Harada T, Tachihara M, Morikawa N, Honda R, Watanabe S, Asao T, Kunisaki M, Fukuhara T, Noro R, Kikuchi E, Tsutani Y, Tenma T, Kobayashi K, Dosaka-Akita H; North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group. Oizumi S, et al. Int J Clin Oncol. 2022 Apr;27(4):676-683. doi: 10.1007/s10147-021-02113-5. Epub 2022 Jan 29. Int J Clin Oncol. 2022. PMID: 35092535 Clinical Trial.
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Tateishi K, et al. Oncologist. 2020 Apr;25(4):e668-e674. doi: 10.1634/theoncologist.2019-0593. Epub 2019 Nov 26. Oncologist. 2020. PMID: 31771990 Free PMC article.
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.
Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Ko R, et al. Oncologist. 2018 Oct;23(10):1210-1217. doi: 10.1634/theoncologist.2017-0586. Epub 2018 Mar 22. Oncologist. 2018. PMID: 29567820 Free PMC article.
15 results